ASH: Ibrutinib Tops Bendamustine + Rituximab for CLL

Improved progression - free survival with ibrutinib for older adults with untreated CLL
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Oncology, Pharmacy, Conference News, Source Type: news